Evidence map›Paper›PMID 31194139›Full record

ArticleRespiratory medicine case reports2019

A case of successful concurrent anti-cancer treatment in a patient who developed follicular lymphoma during treatment with afatinib for advanced lung adenocarcinoma.

Kentaro Masuhiro, Genju Koh, So Takata, Shingo Nasu, Hiromune Takada, Satomu Morita, Ayako Tanaka, Takayuki Shiroyama, Naoko Morishita, Hidekazu Suzuki and 4 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Kentaro MasuhiroDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Genju KohDepartment of Oncology, Yao Tokushukai General Hospital, Osaka, Japan.
So TakataDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Shingo NasuDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Hiromune TakadaDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Satomu MoritaDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Ayako TanakaDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Takayuki ShiroyamaDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Naoko MorishitaDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Hidekazu SuzukiDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Norio OkamotoDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Hiromi KawasumiDepartment of Clinical Laboratory, Osaka Habikino Medical Center, Osaka, Japan.
Chihiro KonishiDepartment of Pharmacy, Yao Tokushukai General Hospital, Osaka, Japan.
Tomonori HirashimaDepartment of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Yao Tokushukai General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present report describes the case of a 64-year-old woman with advanced lung adenocarcinoma expressing mutant epidermal growth factor receptor (EGFR). The patient developed follicular lymphoma during treatment with the EGFR-tyrosine kinase inhibitor afatinib. Standard immunochemotherapy for follicular lymphoma was introduced in addition to continuing treatment with afatinib for lung cancer. Immunochemotherapy was effective and improved the patient's performance status while afatinib controlled the progression of lung cancer. Our case study suggests that it is safe to introduce standard immunochemotherapy for patients who develop malignant lymphoma while continuing treatment with tyrosine kinase inhibitors for lung adenocarcinoma expressing mutant EGFR.

Indexed as

AfatinibALK, anaplastic lymphoma kinaseCT, computed tomographyDouble primary malignant tumorsEGFR-TKIs, epidermal growth factor receptor-tyrosine kinase inhibitorsFL, follicular lymphomaFollicular lymphomaLAD, lung adenocarcinomaLung cancerMetachronousNSCLC, non-small cell lung cancerR-CHOP, cyclophosphamide, doxorubicin, vincristine, predonisone with rituximabSynchronous

Identifiers

PMID31194139
PMCPMC6554495
OpenAlexW2947044710

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.